Oocyte cryopreservation offers women an alternative approach to preserve fertility. We report here the stepwise optimization of a pre-clinical protocol wherein the feasibility of reproducibly cryopreserving human oocytes using failed to fertilized (FTF) MII stage oocytes cryopreserved with the addition of intracellular sugar in clinical practice is demonstrated. Four randomized comparison experiments were performed in a stepwise fashion whereby the experimental condition assessed in one study became the control condition for the following comparison study. Each condition in the experiments contained six replicates. Human FTF MII oocytes obtained from IVF patients under informed consent and IRB approval were utilized in these experiments. Oocytes were injected utilizing micromanipulation techniques with trehalose at an intracellular concentration of approximately 0.1 M. The non- injection control had no intracellular trehalose introduced. Oocytes were cryopreserved in straws in a choline chloride based freezing medium containing 0.4% BSA + 0.5M Trehalose + 0.5M DMSO (or PROH). Straws were seeded at -6 °C, cooled at 1°C/min to -60°C, then 5°C/min to -135°C, followed by plunging to liquid nitrogen. Oocytes were thawed and stepwise diluted in sugar solutions. Optimization of several original reagents and processes was undertaken. Experiments combining reagent changes of BSA to plasmanate, galactose to sucrose and DMEM/F12 to HTF were performed. Process optimization experiments carried out included the evaluation of the Cryo Bio System safety straw, a 30°C water thaw and an alternate sucrose concentration for post thaw dilution. Oocytes were defined as having survived based on the morphological criteria of having an intact zona pellucida, intact oolemma, and a refractive cytoplasm after 24 hour of culture. The results from 48 replicates over two months period are summarized in the Table. Microinjection of intracellular trehalose achieved greater than 60% survival (n=42, 116/182 (63.7%)) through serial optimization experiments. The injection of trehalose into FTF MII stage human oocytes prior to cryopreservation offers consistent and reproducible survival rates. Clinical studies are needed to demonstrate fertilization, embryo development, implantation, clinical pregnancies and live births from oocytes cryopreserved using the method of microinjection of trehalose.